Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 12/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30491786 | 1.00 | AAK1 (0.44) | AAK1CACNA1BSSTR4CNR2DGAT1 | |
| SCHEMBL28995563 | 1.00 | AAK1 (0.44) | AAK1CACNA1BSSTR4CNR2DGAT1 | |
| SCHEMBL25250102 | 0.84 | CNR2 (0.35) | AAK1SSTR4CNR2SCN9A | |
| SCHEMBL25297477 | 0.84 | CNR2 (0.35) | AAK1SSTR4CNR2SCN9A | |
| SCHEMBL25811104 | 0.83 | AAK1 (0.50) | AAK1SCN9ACTSBCTSSCTSK | |
| SCHEMBL25811427 | 0.81 | AAK1 (0.47) | AAK1SCN9ACTSBCTSSCTSK | |
| SCHEMBL28995608 | 0.81 | AAK1 (0.47) | AAK1SCN9ACTSBCTSSCTSK | |
| SCHEMBL25807450 | 0.79 | AAK1 (0.61) | AAK1SCN9A | |
| SCHEMBL28995711 | 0.79 | CNR1 (0.42) | AAK1CACNA1BCNR2CTSSCTSK | |
| SCHEMBL25807492 | 0.79 | CNR1 (0.42) | AAK1CACNA1BCNR2CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BEONE MEDICINES I GMBH (CH) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BIRC2, BIRC3, API5 | AAK1 293/4885CACNA1B 112/4885SSTR4 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.